Scribe Therapeutics, a Bay Area biotech co-founded by Nobel Laureate Dr. Jennifer Doudna, has filed an S-1 registration statement, initiating the IPO process on the Nasdaq Global Market.
While current genetic medicines are largely limited to rare disorders, Scribe is engineering its technologies for use in common diseases. The company is designing CRISPR-based genetic medicines to be well-tolerated, effective, durable and scalable enough to shift the treatment paradigm from symptom-driven intervention and chronic care to population-level prevention.
Scribe’s focus is on cardiovascular and metabolic diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease, or ASCVD. Its lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels.
Scribe is backed by more than $180 million in partnership payments from Sanofi and Eli Lilly.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!